PTGS2 and ovarian carcinoma: Celecoxib, a selective COX-2 inhibitor, can decrease cell growth, increase the cleaved caspase-3 activity and induce cell cycle G1 phase arrest in a dose-dependent manner in ovarian cancer cells (37).